Viewing Study NCT02387957

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:47 PM
Ignite Modification Date: 2026-02-23 @ 4:54 AM
Study NCT ID: NCT02387957
Status: TERMINATED
Last Update Posted: 2024-10-30
First Post: 2015-03-09
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
Sponsor: Ophthotech Corporation
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Age-Related Macular Degeneration View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Wet AMD View
None subfoveal choroidal neovascularization View
None Fovista® View
None Avastin® View
None Lucentis® View
None Eylea® View